MCID: EPN002
MIFTS: 53

Ependymoma malady

Categories: Rare diseases, Neuronal diseases, Cancer diseases, Genetic diseases

Aliases & Classifications for Ependymoma

Aliases & Descriptions for Ependymoma:

Name: Ependymoma 50 56 29 52 69
Tanycytic Ependymoma 50 69
Papillary Ependymoma 50 69
Cellular Ependymoma 50 69
Who Grade Ii Ependymal Neoplasm 50
Epithelial Ependymoma 50
Clear Cell Ependymoma 50
Ependymoma, Familial 50

Characteristics:

Orphanet epidemiological data:

56
ependymoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Orphanet 56 ORPHA251636
UMLS via Orphanet 70 C0014474
ICD10 via Orphanet 34 D43.2

Summaries for Ependymoma

MalaCards based summary : Ependymoma, also known as tanycytic ependymoma, is related to myxopapillary ependymoma and clear cell ependymoma. An important gene associated with Ependymoma is RELA (RELA Proto-Oncogene, NF-KB Subunit), and among its related pathways/superpathways are DNA Damage and Neuroscience. The drugs Vincristine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and bone, and related phenotypes are Increased proliferation and homeostasis/metabolism

Wikipedia : 71 Ependymoma is a tumor that arises from the ependyma, a tissue of the central nervous system. Usually, in... more...

Related Diseases for Ependymoma

Diseases in the Ependymoma family:

Benign Ependymoma Malignant Ependymoma
Malignant Adult Ependymoma

Diseases related to Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 288)
id Related Disease Score Top Affiliating Genes
1 myxopapillary ependymoma 33.7 GFAP NF2 SYP VIM
2 clear cell ependymoma 33.3 MUC1 S100B VIM
3 benign ependymoma 33.1 EGFR MUC1 SYP
4 brain stem ependymoma 33.1 GFAP SYP
5 subependymal glioma 31.3 MKI67 MUC1 VIM
6 childhood medulloblastoma 29.5 ENO2 GFAP SYP
7 anaplastic ependymoma 12.3
8 pediatric ependymoma 12.2
9 malignant ependymoma 11.9
10 spinal cord ependymoma 11.9
11 papillary ependymoma 11.9
12 tanycytic ependymoma 11.9
13 cellular ependymoma 11.9
14 brain ependymoma 11.9
15 pediatric supratentorial ependymoma 11.9
16 pediatric infratentorial ependymoma 11.8
17 low grade ependymoma 11.8
18 mixed astrocytoma-ependymoma 11.7
19 malignant adult ependymoma 11.7
20 adult brain ependymoma 11.7
21 adult spinal cord ependymoma 11.7
22 mixed astrocytoma-ependymoma-oligodendroglioma 11.7
23 parietal lobe ependymoma 11.6
24 glioma 11.1
25 subependymoma 11.1
26 neurofibromatosis, type 2 11.1
27 glioma susceptibility 1 11.0
28 glioma susceptibility 9 10.7
29 diencephalic syndrome 10.7
30 glioma susceptibility 2 10.7
31 multiple endocrine neoplasia 1 10.7
32 glioblastoma 3 10.7
33 diabetes hypogonadism deafness mental retardation 10.4 GFAP SYP
34 papillary tumor of the pineal region 10.4 GFAP SYP
35 lucey-driscoll syndrome 10.3 MUC1 S100B
36 secondary pulmonary hemosiderosis 10.3 MUC1 S100B
37 lupus - neurological sequelae 10.3 S100B VIM
38 intrahepatic bile duct adenoma 10.3 GFAP SYP
39 pilocytic astrocytoma of cerebellum 10.3 GFAP SYP
40 hypothalamic neoplasm 10.3 GFAP NES
41 angiofollicular lymph hyperplasia 10.3 GFAP NES
42 pleomorphic xanthoastrocytoma 10.3 GFAP NF2 SYP
43 invasive mole 10.3 MUC1 S100B
44 vagina leiomyosarcoma 10.3 GFAP MUC1
45 bronchitis 10.3 GFAP NF2
46 children's interstitial lung disease 10.3 GFAP SYP
47 ovarian cystadenoma 10.3 GFAP MUC1 S100B
48 trombiculiasis 10.3 GFAP MUC1 S100B
49 acute generalized exanthematous pustulosis 10.3 RELA S100B
50 melanotic neurilemmoma 10.3 GFAP NF2 SYP

Graphical network of the top 20 diseases related to Ependymoma:



Diseases related to Ependymoma

Symptoms & Phenotypes for Ependymoma

GenomeRNAi Phenotypes related to Ependymoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 MEN1 NF2

MGI Mouse Phenotypes related to Ependymoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.9 EGFR GFAP MEN1 MGMT NF2 RELA
2 respiratory system MP:0005388 9.56 TP73 VIM EGFR ENO2 MGMT NF2
3 vision/eye MP:0005391 9.23 EGFR GFAP NF2 RELA TIMP3 TP73

Drugs & Therapeutics for Ependymoma

Drugs for Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 302)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
2
Etoposide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
4
Methotrexate Approved Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
7
Dacarbazine Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
8
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
9
Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
10
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
11
Valproic Acid Approved, Investigational Phase 2, Phase 3,Phase 1 99-66-1 3121
12
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
13
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
14
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
18
Ondansetron Approved Phase 3 99614-02-5 4595
19
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
20
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
21
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
23 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
24 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
27 Dermatologic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
28 Vitamin B Complex Phase 3,Phase 2,Phase 1,Early Phase 1
29 Etoposide phosphate Phase 3,Phase 2,Phase 1,Early Phase 1
30 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
31 Liver Extracts Phase 3,Phase 2,Phase 1
32 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antimitotic Agents Phase 3,Phase 2,Phase 1
35 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1
38 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
39 pancreatic polypeptide Phase 3,Phase 1
40
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513
41 Analgesics Phase 3,Phase 2,Phase 1
42
Serotonin Phase 3,Phase 2 50-67-9 5202
43 Cholinergic Agents Phase 3,Phase 2
44 Adjuvants, Anesthesia Phase 3
45 Serotonin Agents Phase 3,Phase 2
46 Cholinesterase Inhibitors Phase 3,Phase 2
47 Serotonin Antagonists Phase 3,Phase 2
48 Narcotics Phase 3
49 GABA Agents Phase 2, Phase 3,Phase 1
50 Gastrointestinal Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 231)
id Name Status NCT ID Phase
1 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
2 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
4 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
5 An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3
6 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3
7 Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy Active, not recruiting NCT00683319 Phase 3
8 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Active, not recruiting NCT00749723 Phase 2, Phase 3
9 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Active, not recruiting NCT01346267 Phase 3
10 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
11 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3
12 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2
13 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2
14 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Unknown status NCT00826241 Phase 2
15 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2
16 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors Unknown status NCT02050243 Phase 1, Phase 2
17 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2
18 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2
19 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2
20 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Unknown status NCT01026493 Phase 1, Phase 2
21 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2
22 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2
23 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2
24 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2
25 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2
26 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2
27 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2
28 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Completed NCT01836549 Phase 2
29 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2
30 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2
31 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2
32 A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects Completed NCT00187226 Phase 2
33 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2
34 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
35 Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors Completed NCT00006450 Phase 2
36 A Phase I/II Study of the Photon Radiosurgery System Completed NCT00179907 Phase 1, Phase 2
37 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2
38 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2
39 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2
40 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2
41 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2
42 Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy Completed NCT00463203 Phase 2
43 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2
44 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
45 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2
46 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2
47 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2
48 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2
49 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2
50 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2

Search NIH Clinical Center for Ependymoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Ependymoma

Genetic tests related to Ependymoma:

id Genetic test Affiliating Genes
1 Ependymoma 29

Anatomical Context for Ependymoma

MalaCards organs/tissues related to Ependymoma:

39
Spinal Cord, Brain, Bone, Pituitary, Cerebellum, Temporal Lobe, Medulla Oblongata

Publications for Ependymoma

Articles related to Ependymoma:

(show top 50) (show all 929)
id Title Authors Year
1
Extra-axial ependymoma of the cerebral convexity: A very rare intracranial adult tumor. ( 28059629 )
2017
2
Differentiation of recurrent spinal ependymoma from postradiation treatment necrosis through multiparametric PET-MR and perfusion MRI. ( 27816875 )
2017
3
The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. ( 27858204 )
2017
4
Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma. ( 28089483 )
2017
5
Current therapy and the evolving molecular landscape of paediatric ependymoma. ( 27866097 )
2017
6
Immunohistochemical features of giant cell ependymoma of the filum terminale with unusual clinical and radiological presentation. ( 28088216 )
2017
7
Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database. ( 27423644 )
2016
8
Magnetic resonance imaging findings of extraventricular anaplastic ependymoma: A report of 11 cases. ( 27602137 )
2016
9
Outcome Analysis in Cases of Spinal Conus Cauda Ependymoma. ( 27790509 )
2016
10
Papilledema and Spinal Ependymoma: When Eyes are Windows to the Spinal Cord. ( 27470690 )
2016
11
Toward an integrated histomolecular diagnosis of supratentorial ependymoma. ( 27044295 )
2016
12
Assessing 'second-look' tumour resectability in childhood posterior fossa ependymoma-a centralised review panel and staging tool for future studies. ( 27585992 )
2016
13
MR imaging features that distinguish spinal cavernous angioma from hemorrhagic ependymoma and serial MRI changes in cavernous angioma. ( 27531350 )
2016
14
Concomitant Double Tumors of Myxopapillary Ependymoma Presented at Cauda Equina-Filum Terminale in Adult Patient. ( 27123029 )
2016
15
Primary seeding of a myxopapillary ependymoma: Is it a different disease in an adult population? Case report and review of the literature. ( 28040529 )
2016
16
Bilateral papilloedema as the initial manifestation of spinal ependymoma. ( 26971061 )
2016
17
Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. ( 27863964 )
2016
18
Supratentorial "vascular" variant of ependymoma: a lesser known morphologic variant and a diagnostic pitfall. ( 27392446 )
2016
19
Treatment implications of posterior fossa ependymoma subgroups. ( 27846874 )
2016
20
Spinal myxopapillary ependymoma in an adult male presenting with recurrent acute low back pain: a case report. ( 27092234 )
2016
21
Lipomatous ependymoma: response to query on T1-weighted image. ( 27155965 )
2016
22
Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. ( 27390862 )
2016
23
Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. ( 26690880 )
2016
24
Tanycytic ependymoma of cervical cord presenting with spontaneous intratumoral hemorrhage. ( 27033310 )
2016
25
Ependymoma in supratentorial extra-axial location. ( 27094532 )
2016
26
Supratentorial extraventricular WHO grade III (anaplastic) ependymoma 17 years after total removal of WHO grade II ependymoma of the fourth ventricle. ( 27215793 )
2016
27
Lumbar corpectomy for correction of degenerative scoliosis from osteoradionecrosis reveals a delayed complication of lumbar myxopapillary ependymoma. ( 27056674 )
2016
28
Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. ( 27306443 )
2016
29
Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. ( 27109549 )
2016
30
Squash cytology of tanycytic ependymoma: A report of two cases. ( 27879059 )
2016
31
Extradural sacrococcygeal subcutaneous ependymoma misdiagnosed as pilonidal disease: case report and review of the literature. ( 27432901 )
2016
32
Intramedullary ependymoma: Microsurgical resection technique. ( 27131635 )
2016
33
Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma. ( 27104090 )
2016
34
Quantitative imaging analysis of posterior fossa ependymoma location in children. ( 27117266 )
2016
35
PD1 and PD-L1 in ependymoma might not be therapeutic targets. ( 27841146 )
2016
36
Angiocentric glioma transformed into anaplastic ependymoma: Review of the evidence for malignant potential. ( 27742374 )
2016
37
Acute Paraplegia as a Result of Hemorrhagic Spinal Ependymoma Masked by Spinal Anesthesia: Case Report and Review of Literature. ( 27195260 )
2016
38
WE-FG-202-09: Voxel-Level Analysis of Adverse Treatment Response in Pediatric Patients Treated for Ependymoma with Passive Scattering Proton Therapy. ( 28048899 )
2016
39
Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. ( 27550150 )
2016
40
Spinal cord ependymoma: a review of the literature and case series of ten patients. ( 27154165 )
2016
41
Atypical Teratoid/Rhabdoid Tumor (AT/RT) Arising From Ependymoma: A Type of AT/RT Secondarily Developing From Other Primary Central Nervous System Tumors. ( 26769252 )
2016
42
Tanycytic ependymoma vs pilocytic astrocytoma? Pitfalls in diagnosis. ( 27773093 )
2016
43
Brain Tumor in an In Vitro Fertilization-Facilitated Pregnancy: Fourth Ventricle Anaplastic Ependymoma in the Second Trimester. ( 27330925 )
2016
44
Letter to the Editor: regarding "Lipomatous ependymoma: report of a rare differentiation pattern with a comprehensive review of literature". ( 27379426 )
2016
45
A mixed choroid plexus papilloma and ependymoma. ( 26670168 )
2016
46
miR-15a and miR-24-1 as putative prognostic microRNA signatures for pediatric pilocytic astrocytomas and ependymomas. ( 26813564 )
2016
47
Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. ( 27287856 )
2016
48
SOX10 Distinguishes Pilocytic and Pilomyxoid Astrocytomas From Ependymomas but Shows No Differences in Expression Level in Ependymomas From Infants Versus Older Children or Among Molecular Subgroups. ( 26945037 )
2016
49
Surgical treatment for posttraumatic hemorrhage inside a filum terminale myxopapillary ependymoma: a case report and literature review. ( 27015688 )
2016
50
Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients. ( 26615563 )
2016

Variations for Ependymoma

Cosmic variations for Ependymoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM23159 MEN1 central nervous system,fourth ventricle,glioma,ependymoma Grade III-IV c.1413G>A p.W471* 2

Copy number variations for Ependymoma from CNVD:

7 (show top 50) (show all 1024)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13823 1 1 7200000 Deletion Ependymoma
2 15495 1 116080654 116108285 Amplification NHLH2 Ependymoma
3 15648 1 117745152 117779348 Deletion MAN1A2 Ependymoma
4 19381 1 150034000 245120000 Amplification Ependymoma
5 19382 1 150034000 245120000 Amplification Ependymoma
6 26308 1 198898833 198920273 Amplification LGR6 Ependymoma
7 31595 1 2869431 2902617 Amplification TLR5 Ependymoma
8 31803 1 3118000 5001000 Deletion Ependymoma
9 38299 10 101279725 101300855 Deletion NKX2 Ependymoma
10 38453 10 102724768 102752246 Deletion LZTS2 Ependymoma
11 38454 10 102724768 102752246 Deletion MRPL43 Ependymoma
12 38455 10 102724768 102752246 Deletion PEO1 Ependymoma
13 38456 10 102724768 102752246 Deletion SEMA4G Ependymoma
14 38866 10 105634726 105742493 Deletion OBFC1 Ependymoma
15 38867 10 105634726 105742493 Deletion SLK Ependymoma
16 38979 10 106855945 106907237 Deletion SORCS3 Ependymoma
17 39169 10 11151805 11236375 Deletion CUGBP2 Ependymoma
18 40763 10 13344307 13497936 Deletion PHYH Ependymoma
19 40764 10 13344307 13497936 Deletion SEPHS1 Ependymoma
20 40806 10 133827559 133847021 Amplification C10orf39 Ependymoma
21 40809 10 133852261 133910912 Deletion DPYSL4 Ependymoma
22 40810 10 133852261 133910912 Deletion STK32C Ependymoma
23 40887 10 134410586 134892955 Deletion C10orf92 Ependymoma
24 40888 10 134410586 134892955 Deletion C10orf93 Ependymoma
25 40889 10 134410586 134892955 Deletion GPR123 Ependymoma
26 40890 10 134410586 134892955 Deletion INPP5A Ependymoma
27 40891 10 134410586 134892955 Deletion KNDC1 Ependymoma
28 40892 10 134410586 134892955 Deletion NKX6 Ependymoma
29 41033 10 135073302 135095235 Amplification ECHS1 Ependymoma
30 41034 10 135073302 135095235 Amplification PAOX Ependymoma
31 41074 10 135176625 135276748 Deletion CYP2E1 Ependymoma
32 41075 10 135176625 135276748 Deletion FLJ44653 Ependymoma
33 41076 10 135176625 135276748 Deletion SYCE1 Ependymoma
34 41910 10 25665327 25756077 Deletion GPR158 Ependymoma
35 42307 10 3169189 3180797 Deletion PITRM1 Ependymoma
36 44077 10 5175582 5187881 Deletion AKR1CL1 Ependymoma
37 44224 10 53651276 53712562 Deletion PRKG1 Ependymoma
38 44704 10 6170011 6268419 Deletion RBM17 Ependymoma
39 45199 10 68970214 69114993 Deletion CTNNA3 Ependymoma
40 45273 10 69645873 69701073 Deletion ATOH7 Ependymoma
41 45408 10 70846341 70896472 Deletion TSPAN15 Ependymoma
42 45468 10 71234506 71351772 Deletion COL13A1 Ependymoma
43 45538 10 71990162 72295747 Deletion ADAMTS14 Ependymoma
44 45539 10 71990162 72295747 Deletion C10orf27 Ependymoma
45 45540 10 71990162 72295747 Deletion KIAA1274 Ependymoma
46 45541 10 71990162 72295747 Deletion PRF1 Ependymoma
47 45542 10 71990162 72295747 Deletion SGPL1 Ependymoma
48 45578 10 72636128 72774965 Deletion SLC29A3 Ependymoma
49 45579 10 72636128 72774965 Deletion UNC5B Ependymoma
50 45628 10 73121579 73231404 Deletion C10orf54 Ependymoma

Expression for Ependymoma

Search GEO for disease gene expression data for Ependymoma.

Pathways for Ependymoma

GO Terms for Ependymoma

Cellular components related to Ependymoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.44 EGFR ENO2 GFAP MEN1 MKI67 MUC1

Biological processes related to Ependymoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.16 MUC1 TP73
2 response to cobalamin GO:0033590 8.96 EGFR RELA
3 response to organic cyclic compound GO:0014070 8.92 EGFR MGMT MKI67 RELA

Molecular functions related to Ependymoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.23 EGFR GFAP RELA S100B SYP TP73

Sources for Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....